despite neutral imaging results, adalimumab did improve other key markers of inflammation in the blood including glyca, crp, tnf, and il-6.
.
yet these drugs are not a "home run," says elizabeth loder, md, a professor of neurology at harvard medical school and chief of the division of headache at brigham & women's hospital.
.
.
. 0
.
the staff's "dearth of knowledge" about the correct procedure to follow when someone dies unexpectedly was also highlighted.
.
.
0
.
.
.